Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow declines year over year

Q3 FY2026 free cash flow of $9.21M (cash outflow) fell 89.7% year over year, behind the -38.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 86.1% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Free cash flow amounted to 127.6% of revenue in FY2025, down 94.3 pp from a year earlier.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -89.7% toward the trailing-twelve-month pace of -38.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$9.21M-86.1% QoQ
Last fiscal yearDec 2025
-$336.24M-7.6% YoY
LTMSep 2026
-$216.06M-38.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.7%——
1 year-7.6%——
3-year CAGR+2.4%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(336.24M) USD
Year-over-year change
+7.6%

Free Cash Flow vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.6% is the 9th highest of 10, against a peer median of -8.5%.
  • Free cash flow amounts to 57.0% of revenue for IOVA, versus a peer median of 23.6%.
IOVA Competitors
Free Cash Flow for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$867.34M USD—-31.6%21.0%
BNTXBioNTech SELTM Jun 2026€518.34M EUR+124.1%-72.7%19.6%
LEGNLegend Biotech CorporationLTM Sep 2026$320.88M USD+70.1%-9.1%23.6%
IBRXImmunityBio, Inc.LTM Sep 2026$297.09M USD-8.5%-9.4%162.7%
REPLReplimune Group, Inc.LTM Dec 2025$283.27M USD+47.6%+33.0%—
IMNMImmunome, Inc.LTM Sep 2026$238.7M USD+24.3%+90.7%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$216.06M USD-38.6%+2.4%57.0%
FATEFate Therapeutics, Inc.LTM Mar 2026$108.09M USD-13.6%-26.6%1711.4%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$78.33M USD-28.1%-2.4%—
STTKShattuck Labs, Inc.LTM Mar 2026$41.28M USD-26.9%-27.8%4128.2%
IMCRImmunocore Holdings plcLTM Mar 2026$30.72M USD-217.9%-39.8%8.0%
Peer median (excluding IOVA) —-8.5%-18.0%23.6%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
Deferred Income Tax00(3.48M)(2.83M)(2.07M)
Stock-Based Compensation69.77M84.02M62.63M109.63M61.58M
Change in Working Capital24.55M(2.89M)(6.52M)(122.56M)(24.27M)
Accounts Receivables00(149K)(69.19M)(13.11M)
Inventory00(10.12M)(39.92M)(14.21M)
Accounts Payables6.98M5.88M4.83M(7.84M)(6.66M)
Other Working Capital17.58M(8.78M)(1.08M)(5.61M)9.71M
Other Non-Cash Items6.01M871K(3.54M)(8.65M)6.01M
Operating Cash Flow(227.94M)(292.76M)(361.82M)(352.98M)(302.41M)
Capital Expenditures(37.57M)(20.43M)(22.29M)(11.07M)(33.84M)
Acquisitions (Net)(37.71M)(276.88M)(212.63M)(52.57M)0
Purchases of Investments(725.21M)(245.82M)(205.9M)(460.77M)(318.67M)
Sales of Investments762.91M522.7M285.58M428M400M
Other Investing Activities37.71M276.88M000
Investing Cash Flow132K256.46M(155.24M)(96.41M)47.5M
Debt Repayment1M0000
Common Stock Issued203.16M189.5M463.28M397.3M306.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities35.11M648K(322K)(6.64M)(7.06M)
Financing Cash Flow239.27M190.15M462.96M390.66M300.77M
Effect of Forex Changes00(2.74M)(541K)1.52M
Net Change in Cash11.46M153.85M(56.84M)(59.27M)47.38M
Free Cash Flow(265.52M)(313.18M)(384.11M)(364.05M)(336.24M)

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.